Drug Safety Research and Development, Pfizer Inc., Groton, CT, USA.
Oncology Research and Development, Pfizer Inc., San Diego, CA, USA.
Sci Rep. 2024 Apr 11;14(1):8496. doi: 10.1038/s41598-024-58372-5.
We present a rigorous validation strategy to evaluate the performance of Ultivue multiplex immunofluorescence panels. We have quantified the accuracy and precision of four different multiplex panels (three human and one mouse) in tumor specimens with varying levels of T cell density. Our results show that Ultivue panels are typically accurate wherein the relative difference in cell proportion between a multiplex image and a 1-plex image is less than 20% for a given biomarker. Ultivue panels exhibited relatively high intra-run precision (CV ≤ 25%) and relatively low inter-run precision (CV >> 25%) which can be remedied by using local intensity thresholding to gate biomarker positivity. We also evaluated the reproducibility of cell-cell distance estimates measured from multiplex images which show high intra- and inter-run precision. We introduce a new metric, multiplex labeling efficiency, which can be used to benchmark the overall fidelity of the multiplex data across multiple batch runs. Taken together our results provide a comprehensive characterization of Ultivue panels and offer practical guidelines for analyzing multiplex images.
我们提出了一种严格的验证策略,以评估 Ultivue 多重免疫荧光试剂盒的性能。我们已经在具有不同 T 细胞密度的肿瘤标本中定量评估了四种不同的多重试剂盒(三种人类和一种小鼠)的准确性和精密度。结果表明 Ultivue 试剂盒通常具有较高的准确性,其中给定生物标志物的多重图像和单重图像之间细胞比例的相对差异小于 20%。Ultivue 试剂盒表现出相对较高的内运行精密度(CV≤25%)和相对较低的运行间精密度(CV>>25%),可以通过使用局部强度阈值来判断生物标志物的阳性。我们还评估了从多重图像中测量的细胞间距离估计的可重复性,这些图像表现出较高的内运行和运行间精密度。我们引入了一个新的指标,多重标记效率,可以用于在多个批次运行中对多重数据的整体保真度进行基准测试。总之,我们的结果全面描述了 Ultivue 试剂盒,并为分析多重图像提供了实用的指南。